Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

BACKGROUND AND AIMS: To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-severe ulcerative colitis [UC] from the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment [PURSUIT] studies. METHODS: We analysed golimumab PK and...

Descripción completa

Detalles Bibliográficos
Autores principales: Adedokun, Omoniyi J., Xu, Zhenhua, Marano, Colleen W., Strauss, Richard, Zhang, Hongyan, Johanns, Jewel, Zhou, Honghui, Davis, Hugh M., Reinisch, Walter, Feagan, Brian G., Rutgeerts, Paul, Sandborn, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175493/
https://www.ncbi.nlm.nih.gov/pubmed/27440869
http://dx.doi.org/10.1093/ecco-jcc/jjw133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175493/
https://www.ncbi.nlm.nih.gov/pubmed/27440869
http://dx.doi.org/10.1093/ecco-jcc/jjw133

Ejemplares similares